Race, Pharmacogenomics, and Marketing: Putting BiDil in Context

American Journal of Bioethics 6 (5):W1-W5 (2006)
Abstract
This article endeavors to place into context recent developments surrounding the United States Food and Drug Administration recent approval of BiDil? (isosorbide dinitrate/hydralazine hydrochloride) (NitroMed, Inc., Lexington, MA) as the first ever race-specific drug?in this case to treat heart failure in African Americans. It focuses in particular on both commercial incentives and statistical manipulation of medical data as framing the drive to bring BiDil to market as a race-specific drug. In current discourse about pharmacogenomics, targeting a racial audience is perceived as necessary because at this point the technology and resources do not exist to scan efficiently every individual's genetic profile. The article argues that medical researchers may say they are using race as a surrogate to target biology in drug development, but corporations are using biology as a surrogate to target race in drug marketing. Pharmacogenomics may hold great promise, but on our way to that Promised Land, it is imperative to review such short cuts with a critical eye
Keywords No keywords specified (fix it)
Categories (categorize this paper)
Options
 Save to my reading list
Follow the author(s)
My bibliography
Export citation
Find it on Scholar
Edit this record
Mark as duplicate
Revision history Request removal from index
 
Download options
PhilPapers Archive


Upload a copy of this paper     Check publisher's policy on self-archival     Papers currently archived: 11,365
External links
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
Through your library
References found in this work BETA

No references found.

Citations of this work BETA

No citations found.

Similar books and articles
Jonathan Kahn (2012). The Troubling Persistence of Race in Pharmacogenomics. Journal of Law, Medicine and Ethics 40 (4):873-885.
Karen Peterson-Iyer (2008). Pharmacogenomics, Ethics, and Public Policy. Kennedy Institute of Ethics Journal 18 (1):pp. 35-56.
Analytics

Monthly downloads

Added to index

2010-09-14

Total downloads

6 ( #206,643 of 1,102,744 )

Recent downloads (6 months)

3 ( #120,386 of 1,102,744 )

How can I increase my downloads?

My notes
Sign in to use this feature


Discussion
Start a new thread
Order:
There  are no threads in this forum
Nothing in this forum yet.